Clinical Trial Search

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 97.1; 96.3; 100; 100 percentage of participants

Primary: Number of Participants With Resistance of Ocular Flora to Commonly Used Post-injection Prophylactic Antibiotics — 10; 6 Participants

Primary: Maximum Tolerated Dose (MTD) of Vorinostat Given Orally for 10 Days in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With…

Primary: Periprosthetic Bone Mineral Density (BMD) of Hip — 1.63; 1.64; 1.85; 1.64 g/cm^2

Primary: Number of Participants With Imaging Response in Strata 1 and 2 — 0; 1; 1; 0 participants

Primary: Percentage of Participants Who Achieve a 100% Reduction in Urinary Incontinence Episodes — 32.0; 7.2 percentage of participants

Primary: Percentage of Composite Responders of at Least 2-Level Improvement of Severity — 20; 3 Participants

Primary: Percent Change in Severity of Alopecia Tool (SALT) Score — 30.7 Percent change — p=<0.0001

Primary: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) in the Guselkumab Group Compared to the Placebo…

Primary: Factors Associated With Eaton Classification of Trapeziometacarpal Arthrosis: Age — 61; 66; 75 Years

Primary: Total Dandruff Severity Score (TDSS) — 28.6; 29.3; 26.7; 2.1 units on a scale

Primary: Measure of Response by Change From Baseline to End of Study in BISS Depression and Mania Scale Scores — 35.7; 61.8; 25; 48 percentage change in score on BISS scale…

Primary: Sensitivity — NA Participants

Primary: Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL. — 21.0; 28.6 percentage of participants

Primary: Overall Survival — 68 Months